Additionally, clinical studies revealed that downregulation of EPLIN in tumour samples resulted in poor clinical outcomes in breast cancer24, prostate cancer20,25, lung cancer26, ovarian cancer27 and colorectal cancer23. The gene discussed is LIMA1; the disease is neoplasm.